- Report
- December 2024
- 100 Pages
Global
From €5649EUR$5,950USD£4,765GBP
- Report
- August 2024
- 100 Pages
Global
From €5649EUR$5,950USD£4,765GBP
- Report
- May 2024
- 140 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Report
- May 2024
- 132 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Report
- May 2024
- 128 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Report
- May 2024
- 131 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3560EUR$3,750USD£3,003GBP
- Report
- February 2021
- 420 Pages
United States
From €2278EUR$2,400USD£1,922GBP
- Drug Pipelines
- July 2023
- 30 Pages
Global
From €2611EUR$2,750USD£2,202GBP
- Report
- August 2022
- 30 Pages
Global
From €3085EUR$3,250USD£2,603GBP
- Report
- March 2024
- 397 Pages
Global
From €7547EUR$7,950USD£6,366GBP
- Drug Pipelines
- January 2023
- 30 Pages
United States
From €2611EUR$2,750USD£2,202GBP
- Report
- October 2023
- 145 Pages
Global
From €2990EUR$3,150USD£2,522GBP
- Report
- March 2019
- 33 Pages
Global
€9493EUR$10,000USD£8,008GBP

Brexpiprazole is a medication used to treat mental disorders such as schizophrenia, major depressive disorder, and bipolar disorder. It is a serotonin-dopamine activity modulator (SDAM) that works by balancing the levels of serotonin and dopamine in the brain. Brexpiprazole is a relatively new drug, having been approved by the FDA in 2015. It is available in both oral and injectable forms.
Brexpiprazole is generally well-tolerated and has fewer side effects than other antipsychotic medications. It is also effective in treating symptoms of depression and anxiety. Brexpiprazole is often used as an adjunct to other medications, such as antidepressants, to help improve overall mental health.
The brexpiprazole market is growing as more people are being diagnosed with mental disorders and seeking treatment. It is becoming increasingly popular as a treatment option due to its effectiveness and low side effect profile.
Some companies in the brexpiprazole market include Otsuka Pharmaceuticals, Lundbeck, and Allergan. Show Less Read more